Lexicon rated at sector perform by RBC

RBC Capital Markets analyst Jason Kantor gave Lexicon Genetics Inc. at sector perform, speculative risk, after the company announced plans to begin a phase 1 trial in Europe for LX6171 for cognitive disorders. This marks the start of the company's transformation from a pre-clinical drug discovery company to a company with proprietary clinical development, according to the analyst. Shares of The Woodlands, Texas-based biopharmaceutical company were up 30 cents, or 7.32%, at $4.40 on volume of 631,275 shares versus the three-month running average of 243,055 shares. (Nasdaq: LEXG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.